Clinical trial tracker.

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; not-yet-recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry first/last posted 2026-03-24: randomized triple-masked placebo-controlled Phase 2; estimated n=64; single subcutaneous RE104 30mg vs placebo; primary endpoint HAM-A total-score change at Week 4; estimated completion 2027-04.

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry last update posted 2026-05-06: randomized triple-masked parallel dose-controlled Phase 2; estimated n=100; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7; estimated completion 2026-12.

Last checked 2026-05-15 UTC. Claim boundary: registry/basic-science pharmacology tracker only; healthy-volunteer completion does not establish PTSD efficacy, approval, label, reimbursement, access, or broad safety. Registry: completed Phase 1 randomized triple-masked placebo-controlled 3-period crossover; actual n=26; 300mg R-MDMA vs 100mg S-MDMA vs placebo; primary outcome subjective drug effects on visual analogue scales across study days; completion date 2026-05-12.

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; open-label single-arm Phase 2 design is not efficacy proof and is not approval, label, reimbursement, or access. Registry: single-center fixed-dose 25mg oral psilocybin with therapy in adult women with PTSD secondary to sexual assault; estimated n=70; primary outcomes safety/tolerability via TEAEs/SAEs and C-SSRS from consent/baseline to about eight weeks.

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; CYB003 remains investigational; recruiting/Phase 3 status does not establish efficacy, safety, approval, label, reimbursement, or access. Registry: Phase 3 EMBRACE multicenter randomized quadruple-masked trial, estimated n=330, CYB003 8mg or 16mg in two dosing sessions about three weeks apart vs placebo, adjunctive to antidepressants with psychological support; primary outcome MADRS through Day 84/End of Trial; estimated completion 2027-05-08.

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry and company-presentation schedule watch only; completed Phase 2 status and company-reported presentation plans do not establish approval, label, reimbursement, access, independent efficacy/safety confirmation, or Phase 3 success. Registry last update posted 2026-05-14: completed multicenter randomized triple-masked parallel dose-controlled Phase 2 in postpartum depression; actual n=84; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Enrollment: estimated n=10 | Lead sponsor: Alan Davis | Intervention includes psilocybin + counseling/assessments | Tracker posture: DREAM LUNG oncology/palliative-care proof-of-concept trial watch only; no results claim.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: NOT_YET_RECRUITING | Enrollment: estimated n=76 | Lead sponsor: University of Calgary | Collaborators: Vancouver Island University; University of British Columbia | Intervention: Psilocybin | Tracker posture: psilocybin/PTSD/IPV academic lane; not efficacy, approval, reimbursement, or access evidence.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: NOT_YET_RECRUITING | Enrollment: estimated n=120 | Lead sponsor: Baylor University | Collaborator: Templeton World Charity Foundation | Intervention: Guided Invocation for Mystical Experience | Tracker posture: mystical-experience/integration comparator for consciousness/wiki context; explicitly not psychedelic-drug evidence.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Enrollment: estimated n=32 | Lead sponsor: Resilient Pharmaceuticals | Collaborator: Dr. Vince Clinical Research | Intervention: Midomafetamine HCl | Tracker posture: Phase 1 healthy-volunteer PK/PD/ECG/cardiac-safety characterization; not PTSD efficacy/access.

Last checked: 2026-05-17 07:00 UTC. ClinicalTrials.gov lists NCT06992999 as a not-yet-recruiting randomized, triple-masked Phase 1/2 OCD study, estimated n=20, comparing four psilocybin sessions every three weeks at low dose 10mg vs high dose 30mg; primary outcome safety/tolerability via SAFTEE over 12 months, secondary OCD efficacy measure over 12 months. Claim boundary: registry watch only; no results, no efficacy/safety conclusion, no approval/access/label/reimbursement claim.

Last checked: 2026-05-16 20:00 UTC. ClinicalTrials.gov lists NCT07099534 as a not-yet-recruiting Phase 2, single-group/open-label pilot sponsored by University Hospital, Toulouse. Estimated enrollment 38; two IV ketamine 0.5 mg/kg infusions 24 hours apart plus Good Psychiatric Management; primary outcome is BSL-23 symptom-severity change from baseline to Day 9. Claim boundary: registry/watch and psychiatric-ketamine context only; no results, no randomized proof, no FDA approval/label/access/reimbursement claim, no broad safety claim, and not classic-psychedelic efficacy evidence.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Estimated enrollment: n=30 | Design: randomized, quadruple-masked, dose-controlled | Arms: whole dried psilocybin mushroom in chocolate matrix containing 10mg, 20mg, or 30mg psilocybin; prepared for study by Scottsdale Research Institute per registry | Tracker posture: whole-mushroom/OCD registry-watch only; no efficacy/safety/approval/access claim.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: NOT_YET_RECRUITING | Enrollment: estimated n=50 | Lead sponsor: Washington University School of Medicine | Intervention: Psilocybin (Usona Institute) | Tracker posture: registry/program signal only; does not confirm Usona as psilocybin/MDD CNPV holder.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: TERMINATED | Actual enrollment: n=5 | Why stopped: due to sponsor financial constraints | Lead sponsor: University of Wisconsin, Madison | Collaborator: Revive Therapeutics, Ltd. | Tracker posture: attrition/financing signal for MUD psilocybin study.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: NOT_YET_RECRUITING | Exact registry phases: PHASE2; PHASE3 | Enrollment: estimated n=300 | Lead sponsor: COMPASS Pathways | Intervention: COMP360 psilocybin | Tracker posture: COMP360/PTSD registry-watch lane; keep separate from COMP360/TRD NDA/CNPV lane.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: ACTIVE_NOT_RECRUITING | Actual enrollment: n=238 | Lead sponsor: Usona Institute | Interventions: psilocybin 25 mg; placebo; psilocybin 5 mg; psychosocial support | Tracker posture: Usona Phase 3 sponsorship registry-confirmed; not CNPV-holder confirmation.

ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Enrollment: estimated n=40 | Lead sponsor: University of Colorado, Denver | Collaborators include NIA, UCSF, Emory, Dana-Farber, NYU Langone, University of Nebraska | Tracker posture: INSPIRE older-adult/federally funded research-infrastructure watch; not approval/efficacy evidence.

ClinicalTrials.gov v2 verification on 2026-05-14 plus Red Light Holland/Filament May 14, 2026 company release confirming first-time PEX010 shipment | Overall status: NOT_YET_RECRUITING | Estimated enrollment: n=128 | Phase 2 healthy-adult mechanism study of psilocybin with risperidone/placebo to test role of subjective psychedelic experience | Tracker posture: mechanistic/basic-science study watch; no efficacy/approval/access claim.

Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; estimated enrollment n=250; actual start 2025-01-29; arms placebo, 50µg MM120, 100µg MM120; primary outcome HAM-A total score change baseline to Week 12. Definium May 7/Apr. 22 releases say screening closed / sample-size re-estimation target 200 and topline expected late 3Q 2026; keep registry and company facts separated.

Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=214; actual start 2024-12-11; primary outcome HAM-A total score change baseline to Week 12; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected early 3Q 2026.

ClinicalTrials.gov v2 verification on 2026-05-14 plus Red Light Holland/Filament May 14, 2026 company release identifying UBC as recipient of PEX010 shipment | Overall status: NOT_YET_RECRUITING | Estimated enrollment: n=90 | Phase 3 randomized controlled trial in bipolar-II depression; interventions: psilocybin 25mg and psilocybin 1mg micro-dose | Tracker posture: bipolar-II/TRD psilocybin registry/supply watch; no efficacy/safety/approval/access claim.

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: NOT_YET_RECRUITING | Exact phase: PHASE1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Adult | Interventions: DRUG: 5 Methoxy N,N Dimethyltryptamine; DEVICE: GH001 Aerosol Delivery System | Registry start date type: ESTIMATED (2026-04).

ClinicalTrials.gov manual QA on 2026-04-17 | Recruitment status: Recruiting | Official title: Role of Experience, Conscious Awareness, and Plasticity in Psilocybins Behavioral Effects - Follow-Up Study (The RECAP 2 Study) | Sponsor: University of Wisconsin, Madison | Condition: Psilocybin

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 3 | Lead sponsor: University of North Carolina, Chapel Hill | Conditions: Refractory Depression; Treatment Resistant Depression

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: RECRUITING | Exact phase: NA | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Major Depressive Disorder; Psychedelic Experiences | Interventions: N,N-Dimethyltryptamine; Placebo; Propofol; no sedation

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Not listed | Lead sponsor: University of California, Irvine | Conditions: Opioid Use Disorder (OUD)

Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=149; actual start 2025-04-14; primary outcome MADRS total score change baseline to Week 6; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected late 2Q 2026.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: WITHDRAWN | Exact phase: Early Phase 1 | Lead sponsor: University of Alabama at Birmingham | Conditions: Demoralization

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: RECRUITING | Exact phase: PHASE1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: 5-methoxy-dimethyltryptamine (5-MeO-DMT) | Interventions: DRUG: 0.2 mg/min 5-MeO-DMT; DRUG: 0.4 mg/min 5-MeO-DMT; DRUG: 0.6 mg/min 5-MeO-DMT; DRUG: 0.8 mg/min 5-MeO-DMT; DRUG: Placebo | Registry start date type: ESTIMATED (2026-03-31).

ClinicalTrials.gov v2 verification on 2026-05-14 plus Red Light Holland/Filament May 14, 2026 company release confirming PEX010 shipments | Overall status: RECRUITING | Estimated enrollment: n=120 | Phase 3 double-blind placebo-controlled PSYCHED-PAL-RCT; registry psilocybin microdose dose: 2mg if <55kg or 3mg if ≥55kg on Mon/Tue/Thu/Fri for two weeks | Tracker posture: palliative-care microdose psilocybin trial watch and supply/infrastructure update; company/registry evidence only, not efficacy/approval/access.

Last checked: 2026-05-16 16:00 UTC. Registry: Phase 3 multicentre randomized double-blind controlled COMP360 TRD trial; active not recruiting; actual enrollment 572; actual start 2023-02-14; estimated primary completion 2026-02; estimated completion 2026-12. Arms: COMP360 25 mg, 10 mg, and 1 mg. Primary outcome: COMP360 25 mg versus 1 mg change from baseline in MADRS total score at Week 6. Related company release (2026-02-17) reports COMP006 Part A mean treatment difference -3.8 points vs 1 mg at Week 6 (95% CI -5.8 to -1.8; p<0.001) and 26-week data expected early Q3 2026. Claim boundary: registry + company-topline backfill only; investigational COMP360 is not FDA approved; no label, reimbursement, clinical access, independent FDA efficacy/safety finding, or broad safety claim.

ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine

ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine

ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: University of Sao Paulo | Conditions: Posttraumatic Stress Disorder (PTSD) | Interventions: Ayahuasca; Esketamine

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University of Sao Paulo | Official title: Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial | Condition: Major Depression Severe | Intervention: Ayahuasca; Esketamine | Study type: Interventional | Comparator intervention also includes esketamine, so this row is tagged to both Ayahuasca and Ketamine.

Last checked: 2026-05-17 07:00 UTC. Registry lists NCT05220410 as a completed Phase 2 single-group/open-label psilocybin study in adults with treatment-resistant depression and chronic suicidal ideation; actual n=20; 25mg psilocybin; primary Modified Scale for Suicidal Ideation (MSSI) across Day 1 to Week 12. PubMed PMID 42138588 reports Journal of Clinical Psychiatry open-label publication. Claim boundary: uncontrolled open-label small-study signal only; not randomized proof, not approval/access/label/reimbursement, not suicide-treatment medical advice, and not broad safety proof.

Last checked: 2026-05-16 16:00 UTC. Registry: Phase 3 multicentre randomized double-blind placebo-controlled COMP360 TRD trial; active not recruiting; estimated enrollment 255; actual start 2023-01-19; actual primary completion 2025-05-28; estimated completion 2026-04. Arms: COMP360 psilocybin 25 mg vs placebo. Primary outcome: change from baseline in MADRS total score at Week 6. Related company release (2026-02-17) reports COMP005 Part A mean treatment difference -3.6 points vs placebo at Week 6 (95% CI -5.7 to -1.5; p<0.001). Claim boundary: registry + company-topline backfill only; investigational COMP360 is not FDA approved; no label, reimbursement, clinical access, independent FDA efficacy/safety finding, or broad safety claim.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: University of British Columbia | Conditions: Opioid Dependence; Chronic Pain

ClinicalTrials.gov manual QA on 2026-04-17 | Recruitment status: Not yet recruiting | Official title: A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans | Sponsor: VA Office of Research and Development | Condition: Major Depression

Last checked 2026-05-16 UTC. Claim boundary: registry and company-source backfill only; active-not-recruiting Phase 2 status and company topline claims do not establish approval, label, reimbursement, access, independent efficacy confirmation, broad safety, or Phase 3 success. Registry: randomized quadruple-masked active-controlled Phase 2a in GAD; estimated n=36; two CYB004 medicine sessions ~3 weeks apart plus EMBARK psychotherapy; primary outcome HAM-A across Day 364; actual primary completion 2025-10-14.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Mayo Clinic | Conditions: Depressive Disorder, Treatment-Resistant; Treatment Resistant Depression (TRD)

ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Withdrawn | Official title: Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms | Sponsor: Johns Hopkins University | Conditions: PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries | Interventions: Hormone Replacement Therapy (HRT); Magnetic Resonance Therapy (MeRT); ibogaine with magnesium treatment; 5-MeO-DMT | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Not applicable | Lead sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Psychogenic Nonepileptic Seizures; Psilocybin

ClinicalTrials.gov manual QA on 2026-04-17 | Recruitment status: Recruiting | Official title: Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial | Sponsor: Johns Hopkins University | Condition: Opioid Use Disorder

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: COMPLETED | Exact phase: PHASE2 | Lead sponsor: Beckley Psytech Limited | Conditions: Treatment Resistant Depression | Interventions: DRUG: BPL-003; DRUG: BPL-003 | Asset identity checked against atai/Beckley 2025-10-16 source: BPL-003 is intranasal mebufotenin (5-MeO-DMT) benzoate.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: LSD

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: COMPASS Pathways | Conditions: Post Traumatic Stress Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment-resistant Depression

Last checked 2026-05-16 UTC. Claim boundary: completed pilot comparative-efficacy research backfill only; old single-site open-label/unblinded context and publication signal are not approval, medical advice, clinical access, broad cessation efficacy proof, label, reimbursement, or commercial availability. Registry: actual n=82; psilocybin-assisted 13-week CBT with 30mg/70kg psilocybin on target quit date vs nicotine patch + CBT; primary biologically verified prolonged abstinence at 6 months.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Charles Raison | Conditions: Depression

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study) | Condition: Healthy | Intervention: N,N-Dimethyltryptamine bolus dose arms plus placebo | Study type: Interventional | Official title: Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment. | Condition: Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder | Intervention: Sublingual 5-MeO-DMT microdoses plus psychiatric, cognitive, biochemical, and EEG assessments | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Phase 1/Phase 2 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Major Depression | Interventions: Ayahuasca; placebo

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine | Interventions: N,N-dimethyltryptamine (DMT) + harmine; Placebo

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability and Efficacy of Multiple Sublingual Microdoses of 5-MeO-DMT in Reducing Symptoms of Depression and/or Anxiety. | Condition: Healthy Volunteers | Intervention: BMND08 sublingual 5-MeO-DMT formulation plus monitoring procedures | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Bipolar II Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Postpartum Depression; Postnatal Depression

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: ACTIVE_NOT_RECRUITING | Exact phase: PHASE1 | Lead sponsor: Algernon Pharmaceuticals | Conditions: Stroke | Interventions: N,N-Dimethyltryptamine; Placebo | Notes: Tracker status mapped to Active because ACTIVE_NOT_RECRUITING is not an available status option.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: MAPS Europe B.V. | Conditions: PTSD

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: International Center for Ethnobotanical Education, Research, and Service | Official title: Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone | Condition: Opioid Dependence | Intervention: Ibogaine Hydrochloride | Study type: Interventional

ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Active, not recruiting | Official title: A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Sequelae of Repeated Blast Exposure | Sponsor: Stanford University | Conditions: Blast or Combat Exposure; Head Injury Trauma | Intervention: ibogaine with magnesium treatment | Study type: Observational

ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Completed | Official title: Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | Sponsor: University of Sao Paulo | Condition: Alcoholism | Intervention: Ibogaine Hydrochloride | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Remedy | Conditions: Post Traumatic Stress Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: NO_LONGER_AVAILABLE | Exact phase: Not listed | Lead sponsor: Lykos Therapeutics | Conditions: Post Traumatic Stress Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: MDMA ('Ecstasy'); Social Interaction

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: atai Therapeutics, Inc. | Conditions: Opiate Withdrawal Syndrome

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Not applicable | Lead sponsor: University of Oxford | Conditions: Treatment Resistant Depression; Depression; Major Depressive Disorder

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE2 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Depressive Disorder; Depression, Unipolar | Interventions: N,N-Dimethyltryptamine

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study | Condition: Healthy | Intervention: N,N-Dimethyltryptamine dose-ranging arms plus placebo | Study type: Interventional

Last checked: 2026-05-17 07:00 UTC. Registry lists NCT04630964 as a completed Phase 2 randomized, quadruple-masked, placebo-controlled psilocybin/MDD study at Northern Stockholm Psychiatry with actual n=35; psilocybin 25mg single oral dose vs niacin 100mg, primary MADRS change at Day 8. PubMed PMID 42138922 reports the JAMA Network Open RCT publication. Claim boundary: randomized Phase 2 publication/registry backfill only; not FDA approval, label, reimbursement, access, medical advice, or broad/generalizable safety proof.

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: RECRUITING | Exact phase: PHASE2 | Lead sponsor: University Health Network, Toronto | Conditions: Major Depressive Disorder; Depression; Treatment-Resistant Depression; Mood Disorders | Interventions: DRUG: Single Psychedelic Dose Psilocybin; DRUG: Two Psychedelic Doses Psilocybin

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: WITHDRAWN | Exact phase: Phase 2 | Lead sponsor: Johns Hopkins University | Conditions: Opioid Use Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University of Chicago | Conditions: Healthy; MDMA ('Ecstasy')

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 3 | Lead sponsor: University of Southern California | Conditions: PTSD

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 2 | Lead sponsor: Beckley Med Foundation | Conditions: Bereavement

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Usona Institute | Official title: A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects | Condition: Pharmacokinetics; Safety; Tolerability | Intervention: 5-methoxy-N,N-dimethyltryptamine succinate salt; Placebo | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE1 | Lead sponsor: Reconnect Labs | Conditions: Healthy | Interventions: Dimethyltryptamin (DMT) & Harmine | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE1 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Safety Issues; Healthy Volunteers | Interventions: N,N-Dimethyltryptamine; Placebo

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: Milan Scheidegger | Conditions: Healthy Participants | Interventions: DMT + harmine; Placebo | Notes: Summary explicitly frames Ayahuasca as the relevant plant preparation context.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment Resistant Depression; Major Depressive Disorder; Depression

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: UNKNOWN | Exact phase: Phase 1 | Lead sponsor: Advanced Integrative Medical Science Institute | Conditions: Major Depression; Post Traumatic Stress Disorder | Interventions: SM-001 | Notes: Brief summary describes SM-001 as a standardized Ayahuasca analog. Tracker status mapped to Active because UNKNOWN is not an available status option.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: NYU Langone Health | Conditions: Alcohol Dependence

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Beckley Psytech Limited | Official title: A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects | Condition: Pharmacokinetics in Healthy Adults | Intervention: 5-MeO-DMT; Placebo | Study type: Interventional

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Effects of Dimethyltryptamine (DMT) in Healthy Subjects: A Placebo-controlled Cross-over Study | Condition: Healthy | Intervention: Dimethyltryptamine (DMT); Saline | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: EARLY_PHASE1 | Lead sponsor: Psychiatric University Hospital, Zurich | Conditions: Emotions; Mood; Cognitive Function 1, Social; Empathy | Interventions: DMT; Harmine; Placebo (Harmine); Placebo (DMT) | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: University of California, San Diego | Conditions: Anorexia Nervosa

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: UNKNOWN | Exact phase: PHASE2 | Lead sponsor: King's College London | Conditions: Treatment Resistant Depression | Interventions: COMBINATION_PRODUCT: Psilocybin assisted therapy; COMBINATION_PRODUCT: Placebo assisted therapy | Tracker status mapped to Active because UNKNOWN is not an available Notion status option.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 4 | Lead sponsor: University of Cincinnati | Conditions: Major Depressive Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Not applicable | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: Brigham and Women's Hospital | Conditions: Anxiety Disorder; Cancer

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 4 | Lead sponsor: Sheba Medical Center | Conditions: Treatment Resistant Depression

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Parc de Salut Mar | Conditions: Metabolism; Interaction